# ‚öîÔ∏è CLINICAL TRIAL DOSSIER

**NCT ID**: NCT03902379  
**Trial Title**: Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer  
**Patient ID**: ayesha_001  
**Generated**: 2025-11-14T19:56:29.512263  
**Generated By**: JR2 (Dossier Sidekick)

---

## 1. TRIAL OVERVIEW

**Title**: Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer  
**Phase**:   
**Status**: WITHDRAWN  
**Sponsor**:   
**Estimated Enrollment**: 0  
**Primary Endpoint**: None

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT03902379

---

## 2. ELIGIBILITY ASSESSMENT

**Summary**: 4/5 criteria met

### Eligibility Criteria Table

| Criterion | Status | Confidence | Notes |
|-----------|--------|------------|-------|
| Disease Match | ‚úÖ PASS | 0.90 | Ovarian/gynecologic match: ["endometrial carcinoma", "stage 0 fallopian tube cancer ajcc v7", "stage i fallopian tube cancer ajcc v6 and v7", "stage i ovarian cancer ajcc v6 and v7", "stage ia fallopian tube cancer ajcc v6 and v7", "stage ia ovarian cancer ajcc v6 and v7", "stage ib fallopian tube cancer ajcc v6 and v7", "stage ib ovarian cancer ajcc v6 and v7", "stage ic fallopian tube cancer ajcc v6 and v7", "stage ic ovarian cancer ajcc v6 and v7", "stage ii cervical cancer ajcc v7", "stage ii fallopian tube cancer ajcc v6 and v7", "stage ii ovarian cancer ajcc v6 and v7", "stage ii uterine corpus cancer ajcc v7", "stage iia cervical cancer ajcc v7", "stage iia fallopian tube cancer ajcc v6 and v7", "stage iia ovarian cancer ajcc v6 and v7", "stage iia1 cervical cancer ajcc v7", "stage iia2 cervical cancer ajcc v7", "stage iib cervical cancer ajcc v6 and v7", "stage iib fallopian tube cancer ajcc v6 and v7", "stage iib ovarian cancer ajcc v6 and v7", "stage iic fallopian tube cancer ajcc v6 and v7", "stage iic ovarian cancer ajcc v6 and v7", "stage iii cervical cancer ajcc v6 and v7", "stage iii fallopian tube cancer ajcc v7", "stage iii ovarian cancer ajcc v6 and v7", "stage iii primary peritoneal cancer ajcc v7", "stage iii uterine corpus cancer ajcc v7", "stage iiia cervical cancer ajcc v6 and v7", "stage iiia fallopian tube cancer ajcc v7", "stage iiia ovarian cancer ajcc v6 and v7", "stage iiia primary peritoneal cancer ajcc v7", "stage iiia uterine corpus cancer ajcc v7", "stage iiib cervical cancer ajcc v6 and v7", "stage iiib fallopian tube cancer ajcc v7", "stage iiib ovarian cancer ajcc v6 and v7", "stage iiib primary peritoneal cancer ajcc v7", "stage iiib uterine corpus cancer ajcc v7", "stage iiic fallopian tube cancer ajcc v7", "stage iiic ovarian cancer ajcc v6 and v7", "stage iiic primary peritoneal cancer ajcc v7", "stage iiic uterine corpus cancer ajcc v7", "stage iiic1 uterine corpus cancer ajcc v7", "stage iiic2 uterine corpus cancer ajcc v7", "stage iv cervical cancer ajcc v6 and v7", "stage iv fallopian tube cancer ajcc v6 and v7", "stage iv ovarian cancer ajcc v6 and v7", "stage iv primary peritoneal cancer ajcc v7", "stage iv uterine corpus cancer ajcc v7", "stage iva cervical cancer ajcc v6 and v7", "stage iva uterine corpus cancer ajcc v7", "stage ivb cervical cancer ajcc v6 and v7", "stage ivb uterine corpus cancer ajcc v7", "uterine carcinosarcoma", "uterine corpus sarcoma"] |
| Treatment Line | ‚úÖ PASS | 0.80 | Line match assumed (not explicitly excluded) |
| Biomarker Requirements | ‚úÖ PASS | 1.00 | No biomarker requirements |
| Location (NYC Metro) | ‚úÖ PASS | 0.50 | No location data (assume match) |
| Inclusion Criteria (Full Text Available) | üìã REVIEW | 0.80 | See full text: Inclusion Criteria:

* Newly diagnosed with any stage of primary ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer in the past 6 months
* Newly diagnosed with high grade stag... |

---

## 3. STRATEGIC SCENARIOS

### Best Case

**Eligibility Probability**: 80.0%

**Scenario**: All pending biomarker tests return favorable results

**Eligibility Level**: HIGH

### Most Likely

**Eligibility Probability**: 80.0%

**Scenario**: 50% of pending tests pass, some may require additional screening

**Eligibility Level**: MODERATE

### Challenge

**Eligibility Probability**: 80.0%

**Scenario**: Some pending tests fail, may need alternative trials

**Eligibility Level**: LOW

---

## 4. TACTICAL RECOMMENDATIONS

| Action | Lab | Cost | Timeline | Priority | Rationale |
|--------|-----|------|----------|----------|----------|
| Proceed with trial enrollment | N/A | N/A | Immediate | HIGH | All eligibility criteria met |

---

## 5. DRUG MECHANISMS

### Internet-Based

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for Internet-Based

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

### Quality-of-Life

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for Quality-of-Life

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

### Questionnaire

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for Questionnaire

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

### Survey

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for Survey

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

---

## 6. LOCATION DETAILS

No location data available.

---

## 7. TIMELINE

**Study Start Date**: 

**Primary Completion Date**: 

---

## 8. FULL ELIGIBILITY TEXT

### Inclusion Criteria

Inclusion Criteria:

* Newly diagnosed with any stage of primary ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer in the past 6 months
* Newly diagnosed with high grade stage 2, any grade stage 3 or higher endometrial cancer in the past 6 months
* Newly diagnosed with stage 2 or higher cervical cancer within the past 6 months
* Newly diagnosed with any stage uterine cancer (both sarcoma and carcinosarcoma) in the past 6 months
* At the time of recruitment the patient is on active treatment defined as either currently receiving chemotherapy or radiation or less than 6 months post-cancer surgery
* At the time of recruitment, a Karnofsky performance status of 80 or above or an Eastern Cooperative Oncology Group (ECOG) (80) score of 0 or 1
* English speaking
* Has internet access
* Must give informed consent within 6 months of diagnosis

### Exclusion Criteria

N/A

---

## 9. CONTACT INFORMATION

Contact information not available.

---

## 10. PROVENANCE

**Generated By**: JR2

**Data Sources**: SQLite, Diffbot, DRUG_MECHANISM_DB

**Confidence Flags**: [INFERRED], [NEEDS VERIFICATION]

---

**RESEARCH USE ONLY (RUO)** - This dossier is for research purposes only and should not be used for clinical decision-making without proper medical review.

